Profile data is unavailable for this security.
About the company
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
- Revenue in USD (TTM)1.10bn
- Net income in USD186.50m
- Incorporated2004
- Employees600.00
- LocationPrestige Consumer Healthcare Inc660 White Plains Rd.TARRYTOWN 10591United StatesUSA
- Phone+1 (914) 524-6800
- Fax+1 (302) 655-5049
- Websitehttps://www.prestigebrands.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.58bn | 323.00 | -- | 7.70 | -- | 7.05 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.75bn | 705.00 | 73.08 | 6.84 | 58.84 | 2.70 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.92bn | 674.00 | -- | 2.77 | 43.97 | 4.28 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.99bn | 181.00 | 14.20 | 3.26 | 11.71 | 5.17 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 3.01bn | 979.00 | -- | 6.60 | -- | 7.69 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.16bn | 600.00 | 17.66 | 1.73 | 14.59 | 2.86 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Arcutis Biotherapeutics Inc | 317.93m | -44.32m | 3.17bn | 342.00 | -- | 19.68 | -- | 9.96 | -0.3545 | -0.3545 | 2.49 | 1.31 | 0.7866 | 1.75 | 3.63 | 929,616.90 | -10.97 | -61.20 | -16.53 | -68.48 | 89.96 | -- | -13.94 | -406.29 | 3.28 | -2.61 | 0.407 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Liquidia Corp | 69.22m | -121.85m | 3.32bn | 157.00 | -- | 150.39 | -- | 48.01 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 597.97m | 35.92m | 3.44bn | 315.00 | 101.19 | 6.39 | 91.94 | 5.75 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 3.62bn | 68.00 | 88.47 | 3.80 | 43.70 | 14.40 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| ADMA Biologics Inc | 488.56m | 209.45m | 3.83bn | 677.00 | 18.98 | 8.89 | 17.61 | 7.84 | 0.8476 | 0.8476 | 1.98 | 1.81 | 1.02 | 1.20 | 5.20 | 721,652.90 | 43.67 | -2.99 | 48.83 | -3.39 | 54.71 | 34.09 | 42.87 | -4.56 | 3.65 | 26.62 | 0.1438 | -- | 65.15 | 70.79 | 800.00 | -- | 17.60 | -- |
Data as of Feb 13 2026. Currency figures normalised to Prestige Consumer Healthcare Inc's reporting currency: US Dollar USD
58.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.80m | 14.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.00m | 10.41% |
| Ariel Investments LLCas of 31 Dec 2025 | 4.10m | 8.53% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.46m | 5.12% |
| Kayne Anderson Rudnick Investment Management LLCas of 31 Dec 2025 | 2.14m | 4.45% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.99m | 4.14% |
| Nomura Investment Management Business Trustas of 30 Sep 2025 | 1.62m | 3.37% |
| Allspring Global Investments LLCas of 31 Dec 2025 | 1.61m | 3.35% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.43m | 2.98% |
| Westwood Management Corp. (Texas)as of 30 Sep 2025 | 1.14m | 2.38% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
